FdaApplication

BLA 103779

Back to search

Identifiers

Properties

PropertyValue
applicant_nameWyeth Pharmaceuticals LLC
application_typeBLA
approval_date2001-06-27

Revenue by product

REFACTO

PeriodRevenue
FY 2023$230.0M
FY 2022$239.0M
FY 2021$304.0M

Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients.

Products (4)

ProductActive ingredientStrengthDosage form
REFACTO—250IUFor Injection
REFACTO—1000IUFor Injection
REFACTO—500IUFor Injection
REFACTO—2000IUFor Injection

4 products